Metsera, Inc. Common Stock (MTSR NASDAQ) stock market data APIs
$27.1126
0.31(1.1%)
as of July 1, 2025
Try our APIs with
free plan!
Metsera, Inc. Common Stock Financial Data Overview
Price chart is built with
Anychart
Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity, as well as MET-815i to reduce weight or prevents weight gain. The company was incorporated in 2022 and is based in New York, New York.
Prev. Close
27.1126
Open
27.4244
High
29.5599
Low
26.757
52 wk Range
12.3-37.986
Market Cap
3 090 M
Shares Outstanding
15 000 K
EPS
-0.7303
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Metsera, Inc. Common Stock data using free add-ons & libraries
Get Metsera, Inc. Common Stock Fundamental Data
Metsera, Inc. Common Stock Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-12
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Metsera, Inc. Common Stock News
New
Wall Street Analysts See an 89.66% Upside in Metsera Inc. (MTSR): Can the Stock Really Move This High?
Metsera Inc. (MTSR) closed the last trading session at $29.00, gaining 6.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Stre...
Lilly, Novo, and Amgen set for key obesity trial readouts at upcoming ADA event
[GLP-1 related drugs newspaper headlines with hand and magnifying glass] Leading weight loss drug developers Eli Lilly (NYSE:LLY [https://seekingalpha.com/symbol/LLY]), Novo Nordisk (NVO [https://see...
Metsera stock initiated at overweight by Wells Fargo on obesity drug
Investing.com - Wells Fargo initiated coverage on Metsera Inc (NASDAQ:MTSR), a $2.91 billion biotech company trading at $27.71, with an overweight rating and a $65.00 price target on Friday. The pri...
Eli Lilly’s early-stage obesity drug causes up to 11% of weight loss in three months
[Indianapolis - April 2016: Eli Lilly and Company VII] jetcityimage/iStock Editorial via Getty Images Eli Lilly’s (NYSE:LLY [https://seekingalpha.com/symbol/LLY]) experimental obesity therapy elora...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
